Detalhe da pesquisa
1.
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
Breast Cancer Res;
26(1): 35, 2024 03 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38429789
2.
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
N Engl J Med;
380(8): 741-751, 2019 02 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30786188
3.
Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study.
Breast Cancer Res Treat;
191(2): 389-399, 2022 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34705147
4.
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
BMC Cancer;
22(1): 1107, 2022 Oct 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36309653
5.
Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval.
Breast Cancer Res Treat;
187(3): 883-891, 2021 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33625615
6.
New Persistent Opioid and Benzodiazepine Use After Curative-Intent Treatment in Patients With Breast Cancer.
J Natl Compr Canc Netw;
19(1): 29-38, 2021 01 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33406490
7.
Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trials.
Cancer;
126(19): 4289-4293, 2020 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32697381
8.
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
Breast Cancer Res Treat;
184(1): 53-62, 2020 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32803633
9.
RX-5902, a novel ß-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
BMC Cancer;
20(1): 1063, 2020 Nov 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33148223
10.
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
Invest New Drugs;
37(3): 461-472, 2019 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30229512
11.
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
Breast Cancer Res;
20(1): 82, 2018 08 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30071865
12.
A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.
Oncologist;
23(12): 1409-e140, 2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30139840
13.
Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.
Anticancer Drugs;
29(9): 827-838, 2018 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30048249
14.
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
Invest New Drugs;
35(4): 471-477, 2017 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28105566
15.
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.
Invest New Drugs;
35(5): 627-633, 2017 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28283779
16.
An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer.
BMC Genomics;
16 Suppl 12: S2, 2015.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26681397
17.
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.
Invest New Drugs;
33(3): 691-9, 2015 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25895965
18.
Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study.
Eur J Cancer;
196: 113426, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38000217
19.
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
J Immunother Cancer;
12(2)2024 Feb 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38309722
20.
A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors.
Cancers (Basel);
16(8)2024 Apr 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38672538